410 related articles for article (PubMed ID: 30390797)
1. A Guide to Run Affinity Screens Using Differential Scanning Fluorimetry and Surface Plasmon Resonance Assays.
Bergsdorf C; Wright SK
Methods Enzymol; 2018; 610():135-165. PubMed ID: 30390797
[TBL] [Abstract][Full Text] [Related]
2. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads.
Bergsdorf C; Ottl J
Expert Opin Drug Discov; 2010 Nov; 5(11):1095-107. PubMed ID: 22827747
[TBL] [Abstract][Full Text] [Related]
3. Applications of Biophysics in High-Throughput Screening Hit Validation.
Genick CC; Barlier D; Monna D; Brunner R; Bé C; Scheufler C; Ottl J
J Biomol Screen; 2014 Jun; 19(5):707-14. PubMed ID: 24695619
[TBL] [Abstract][Full Text] [Related]
4. Hit-to-Lead: Hit Validation and Assessment.
Hevener KE; Pesavento R; Ren J; Lee H; Ratia K; Johnson ME
Methods Enzymol; 2018; 610():265-309. PubMed ID: 30390802
[TBL] [Abstract][Full Text] [Related]
5. A combinatorial biophysical approach; FTSA and SPR for identifying small molecule ligands and PAINs.
Redhead M; Satchell R; Morkūnaitė V; Swift D; Petrauskas V; Golding E; Onions S; Matulis D; Unitt J
Anal Biochem; 2015 Jun; 479():63-73. PubMed ID: 25837771
[TBL] [Abstract][Full Text] [Related]
6. Experiences in fragment-based lead discovery.
Hubbard RE; Murray JB
Methods Enzymol; 2011; 493():509-31. PubMed ID: 21371604
[TBL] [Abstract][Full Text] [Related]
7. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
[TBL] [Abstract][Full Text] [Related]
8. waveRAPID-A Robust Assay for High-Throughput Kinetic Screens with the Creoptix WAVEsystem.
Kartal Ö; Andres F; Lai MP; Nehme R; Cottier K
SLAS Discov; 2021 Sep; 26(8):995-1003. PubMed ID: 34049465
[TBL] [Abstract][Full Text] [Related]
9. Biophysical screening for the discovery of small-molecule ligands.
Ciulli A
Methods Mol Biol; 2013; 1008():357-88. PubMed ID: 23729259
[TBL] [Abstract][Full Text] [Related]
10. Combining biophysical screening and X-ray crystallography for fragment-based drug discovery.
Hennig M; Ruf A; Huber W
Top Curr Chem; 2012; 317():115-43. PubMed ID: 21837555
[TBL] [Abstract][Full Text] [Related]
11. High-throughput differential scanning fluorimetry (DSF) and cellular thermal shift assays (CETSA): Shifting from manual to automated screening.
Hansel CS; Lanne A; Rowlands H; Shaw J; Collier MJ; Plant H
SLAS Technol; 2023 Dec; 28(6):411-415. PubMed ID: 37598756
[TBL] [Abstract][Full Text] [Related]
12. Novel trends in high-throughput screening.
Mayr LM; Bojanic D
Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
[TBL] [Abstract][Full Text] [Related]
13. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance.
Giannetti AM
Methods Enzymol; 2011; 493():169-218. PubMed ID: 21371592
[TBL] [Abstract][Full Text] [Related]
14. Biophysics: for HTS hit validation, chemical lead optimization, and beyond.
Genick CC; Wright SK
Expert Opin Drug Discov; 2017 Sep; 12(9):897-907. PubMed ID: 28658992
[TBL] [Abstract][Full Text] [Related]
15. SPR-based fragment screening: advantages and applications.
Neumann T; Junker HD; Schmidt K; Sekul R
Curr Top Med Chem; 2007; 7(16):1630-42. PubMed ID: 17979772
[TBL] [Abstract][Full Text] [Related]
16. Open access high throughput drug discovery in the public domain: a Mount Everest in the making.
Roy A; McDonald PR; Sittampalam S; Chaguturu R
Curr Pharm Biotechnol; 2010 Nov; 11(7):764-78. PubMed ID: 20809896
[TBL] [Abstract][Full Text] [Related]
17. Mass spectrometry for fragment screening.
Chan DS; Whitehouse AJ; Coyne AG; Abell C
Essays Biochem; 2017 Nov; 61(5):465-473. PubMed ID: 28986384
[TBL] [Abstract][Full Text] [Related]
18. PAIN(S) relievers for medicinal chemists: how computational methods can assist in hit evaluation.
Stork C; Kirchmair J
Future Med Chem; 2018 Jul; 10(13):1533-1535. PubMed ID: 29956552
[No Abstract] [Full Text] [Related]
19. Biophysics in drug discovery: impact, challenges and opportunities.
Renaud JP; Chung CW; Danielson UH; Egner U; Hennig M; Hubbard RE; Nar H
Nat Rev Drug Discov; 2016 Oct; 15(10):679-98. PubMed ID: 27516170
[TBL] [Abstract][Full Text] [Related]
20. An Automated Microscale Thermophoresis Screening Approach for Fragment-Based Lead Discovery.
Linke P; Amaning K; Maschberger M; Vallee F; Steier V; Baaske P; Duhr S; Breitsprecher D; Rak A
J Biomol Screen; 2016 Apr; 21(4):414-21. PubMed ID: 26637553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
